Adrenoleukodystrophy (ALD)- Epidemiology Forecast to 2027

  • ID: 4520730
  • Report
  • 65 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 3
This report titled ‘Adrenoleukodystrophy (ALD)- Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Adrenoleukodystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Adrenoleukodystrophy Epidemiology

The Adrenoleukodystrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Adrenoleukodystrophy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Adrenoleukodystrophy Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, diagnosed prevalence of ALD by clinical manifestations (cerebral ALD, Adrenomyleoneuropathy and Addison’s disease), diagnosed prevalence of CALD by segmentation (childhood, adolescent, adult ALD)] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to this research, total prevalent cases of Adrenoleukodystrophy in 7 major markets are found out to be 26,866 in 2016.

Report Scope:
  • The report covers detailed overview of Adrenoleukodystrophy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Adrenoleukodystrophy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Adrenoleukodystrophy by clinical manifestation and diagnosed prevalent cases of CALD by segmentation in 7MM
Key Strengths:
  • 10 Year Forecast of Adrenoleukodystrophy epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Adrenoleukodystrophy
  • Prevalent Cases according to segmentation: Adrenoleukodystrophy by clinical manifestation and diagnosed prevalent cases of CALD by segmentation in 7MM
  • Diagnosed cases of Adrenoleukodystrophy
Key Assessments:
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Key Insights

2. Disease Background and Overview: Adrenoleukodystrophy (ALD)
2.1. Introduction
2.2. Clinical aspects of ALD
2.3. Disease Causes
2.4. Inheritance pattern of ALD
2.5. ALD-Symptoms
2.6. Pathogenesis
2.7. ALD Diagnosis
2.8. X-ALD Newborn Screening
2.9. Tools for evaluating Cerebral X-ALD

3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Disease Definition
3.3. Population and Forecast Parameters

4. 7MM Prevalent Population of Adrenoleukodystophy (ALD)

5. Country Wise-Epidemiology of Adrenoleukodystrophy (ALD)
5.1. United States
5.1.1. Prevalent Population of Adrenoleukodystrophy in United States
5.1.2. Diagnosed Prevalence of ALD by Clinical Manifestation in United States
5.1.3. Diagnosed Prevalence of CALD by Segmentation in United States
5.2. Germany
5.2.1. Prevalent Population of Adrenoleukodystrophy in Germany
5.2.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany
5.2.3. Diagnosed Prevalence of CALD by Segmentation in Germany
5.3. France
5.3.1. Prevalent Population of Adrenoleukodystrophy in France
5.3.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the France
5.3.3. Diagnosed Prevalence of CALD by Segmentation in France
5.4. Italy
5.4.1. Prevalent Population of Adrenoleukodystrophy in Italy
5.4.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy
5.4.3. Diagnosed Prevalence of CALD by Segmentation in Italy
5.5. Spain
5.5.1. Prevalent Population of Adrenoleukodystrophy in Spain
5.5.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain
5.5.3. Diagnosed Prevalence of CALD by Segmentation in Spain
5.6. United Kingdom
5.6.1. Prevalent Population of Adrenoleukodystrophy in United Kingdom
5.6.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the United Kingdom
5.6.3. Diagnosed Prevalence of CALD by Segmentation in United Kingdom
5.7. Japan
5.7.1. Prevalent Population of Adrenoleukodystrophy in Japan
5.7.2. Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan
5.7.3. Diagnosed Prevalence of CALD by Segmentation in Japan

6. Appendix

7. Report Methodology
7.1. Sources used

8. Capabilities

9. Disclaimer

10. About the Publisher

List of Tables
Table 1: X-ALD Phenotypes in Males
Table 2: Phenotype in Female X-ALD carriers
Table 3: the X-ALD Phenotypes
Table 4: MRI Severity Scale
Table 5: MRI Severity Rating (Loes Score)
Table 6: Neurological Function Score (NFS Score)
Table 7: X-linked Adrenoleukodystrophy- Disability Rating Scale (ALD-DRS)
Table 8: Prevalent Population of Adrenoleukodystophy in the 7MM (2016-2027)
Table 9: Prevalent Population of Adrenoleukodystrophy in United States (2016-2027)
Table 10: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2027)
Table 11: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2027)
Table 12: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2027)
Table 13: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2027)
Table 14: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2027)
Table 15: Prevalent Population of Adrenoleukodystrophy in France (2016-2027)
Table 16: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2027)
Table 17: Diagnosed Prevalence of CALD by Segmentation in France (2016-2027)
Table 18: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2027)
Table 19: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2027)
Table 20: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2027)
Table 21: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2027)
Table 22: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2027)
Table 23: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2027)
Table 24: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2027)
Table 25: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2027)
Table 26: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2027)
Table 27: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2027)
Table 28: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2027)
Table 29: Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2027)

List of Figures
Figure 1: Evolution of Phenotypes in X-ALD
Figure 2: Clinical Spectrum of X-ALD
Figure 3: Inheritance spectrum of X-ALD
Figure 4: Pathogenesis of VLCFA
Figure 5: Principles of ALD 3-tier screening
Figure 6: Diagnostic algorithm for diagnosis of adrenoleukodystrophy
Figure 7: Prevalent Population of X-Adrenoleukodystophy in the 7MM (2016-2027)
Figure 8: Prevalent Population of Adrenoleukodystrophy in United States (2016-2027)
Figure 9: Diagnosed Prevalence of ALD by Clinical Manifestation in the United States (2016-2027)
Figure 10: Diagnosed Prevalence of CALD by Segmentation in United States (2016-2027)
Figure 11: Prevalent Population of Adrenoleukodystrophy in Germany (2016-2027)
Figure 12: Diagnosed Prevalence of ALD by Clinical Manifestation in the Germany (2016-2027)
Figure 13: Diagnosed Prevalence of CALD by Segmentation in Germany (2016-2027)
Figure 14: Prevalent Population of Adrenoleukodystrophy in France (2016-2027)
Figure 15: Diagnosed Prevalence of ALD by Clinical Manifestation in the France (2016-2027)
Figure 16: Diagnosed Prevalence of CALD by Segmentation in France (2016-2027)
Figure 17: Prevalent Population of Adrenoleukodystrophy in Italy (2016-2027)
Figure 18: Diagnosed Prevalence of ALD by Clinical Manifestation in the Italy (2016-2027)
Figure 19: Diagnosed Prevalence of CALD by Segmentation in Italy (2016-2027)
Figure 20: Prevalent Population of Adrenoleukodystrophy in Spain (2016-2027)
Figure 21: Diagnosed Prevalence of ALD by Clinical Manifestation in the Spain (2016-2027)
Figure 22: Diagnosed Prevalence of CALD by Segmentation in Spain (2016-2027)
Figure 23: Prevalent Population of Adrenoleukodystrophy in United Kingdom (2016-2027)
Figure 24: Diagnosed Prevalence of ALD by Clinical Manifestation in the UK (2016-2027)
Figure 25: Diagnosed Prevalence of CALD by Segmentation in United Kingdom (2016-2027)
Figure 26: Prevalent Population of Adrenoleukodystrophy in Japan (2016-2027)
Figure 27: Diagnosed Prevalence of ALD by Clinical Manifestation in the Japan (2016-2027)
Figure 28 Diagnosed Prevalence of CALD by Segmentation in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll